Healthcare
Krystal Biotech, Inc.(KRYS)
Live Price
Offline$348.06
+1.87% today
1Y Change
+144.25%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $7.80B
- Revenue Growth
- +33.9%
- EPS Growth
- +126.9%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Krystal Biotech, Inc. (KRYS) is a Healthcare stock with a market cap of $7.80B and listed on NASDAQ. The stock last traded around $348.06 and up 144.3% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of +33.9%, EPS growth of +126.9%, a dividend yield of 0.0%. What stands out right now is revenue +33.9%, EPS +126.9%, free cash flow +58.5% with operating margin 41.5% and ROIC 13.1%. Valuation already assumes a fairly strong business story at P/E 37.4 and price/sales 20.0. Stock Foundry combines KRYS price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+33.9% vs +7.6% peer median
Operating Margin
Above sector median
+41.5% vs +19.4% peer median
P/E
Near sector median
37.4 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 5, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +33.9% and EPS at +126.9%, with operating margin around 41.5%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +0.9% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 5, 2026 | โ | +1.6% | +9.0% | +6.1% |
2026 Feb 17, 2026 | +4.9% | -1.6% | -7.3% | -10.9% |
2025 Nov 3, 2025 | +137.5% | +2.7% | +0.8% | +8.7% |
Benchmark Edge
KRYS vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
KRYS
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
KRYS Max Drawdown
-15.94%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for KRYS and SPY.
Company Overview
Krystal Biotech, Inc.
NASDAQ Global Market
Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
- Leadership
- Krish S. Krishnan
- IPO Date
- Sep 20, 2017
- Employees
- 275
- Street Address
- 2100 Wharton Street
- Mailing
- Pittsburgh, PA, 15203
- Region
- Pittsburgh, PA, US
- Reporting Currency
- USD
- Investor Line
- 412 586 5830
- Last Updated
- May 1, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 37.4
- EV/EBITDA
- 43.5
- Price/Sales
- 20.0
- Price/Book
- 6.3
Growth
- Revenue
- +33.9%
- EPS
- +126.9%
- Free Cash Flow
- +58.5%
Profitability
- Gross Margin
- 92.6%
- Operating Margin
- 41.5%
- Net Margin
- 52.6%
- ROE
- 18.7%
- ROIC
- 13.1%
Balance Sheet
- Debt/Equity
- 0.01
- Current Ratio
- 9.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.